NeuraxisNRXS
NRXS
About: Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
Employees: 21
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
33% more funds holding
Funds holding: 9 [Q3] → 12 (+3) [Q4]
19% more capital invested
Capital invested by funds: $790K [Q3] → $939K (+$150K) [Q4]
2.0% more ownership
Funds ownership: 3.73% [Q3] → 5.73% (+2.0%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for NRXS.
Financial journalist opinion
Positive
Zacks Investment Research
1 month ago
NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth
NRXS records strong revenue growth, expanded insurance coverage and new FDA clearances in fourth-quarter 2024.
Neutral
Seeking Alpha
1 month ago
NeurAxis, Inc. (NRXS) Q4 2024 Earnings Call Transcript
NeurAxis, Inc. (NYSE:NRXS ) Q4 2024 Earnings Conference Call March 20, 2025 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Operator Good day, and thank you for standing by. Welcome to the NeurAxis' Fourth Quarter 2024 Financial Results Conference Call.
Neutral
GlobeNewsWire
1 month ago
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
CARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2024 for the period ended December 31, 2024.
Neutral
GlobeNewsWire
1 month ago
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025
CARMEL, Ind., March 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its fourth quarter and fiscal year 2024, for the period ended December 31, 2024, on Thursday, March 20, 2025, before market open. The Company has scheduled a conference call for the same day, Thursday, March 20, 2025, at 9:00 am ET to review the results.
Neutral
GlobeNewsWire
3 months ago
UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States
CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with a prominent insurer, with approximately 5.1 million members across 13 states.
Neutral
GlobeNewsWire
3 months ago
NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States
CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with Molina Healthcare. Molina, with over 40 years in operation, has approximately 5.1 million members across 13 states.
Neutral
GlobeNewsWire
3 months ago
NeurAxis Inc. Issues Letter to Shareholders
CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that CEO Brian Carrico has published a letter to shareholders highlighting the Company's achievements in 2024 and vision for 2025.
Neutral
GlobeNewsWire
3 months ago
NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
CARMEL, Ind., Jan. 06, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that CEO Brian Carrico will participate in a webcasted company presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.
Neutral
Seeking Alpha
5 months ago
NeurAxis, Inc (NRXS) Q3 2024 Earnings Call Transcript
NeurAxis, Inc (NYSE:NRXS ) Q3 2024 Results Conference Call November 12, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Operator Good day, and thank you for standing by. Welcome to the NeurAxis's Third Quarter 2024 Financial Results Conference Call.
Positive
Zacks Investment Research
5 months ago
NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage
NRXS reports strong third-quarter results with rising revenues, reduced losses and expanded insurance coverage, driving its stock to outperform the market.
Charts implemented using Lightweight Charts™